Copyright
©The Author(s) 2021.
World J Gastroenterol. Jun 21, 2021; 27(23): 3396-3412
Published online Jun 21, 2021. doi: 10.3748/wjg.v27.i23.3396
Published online Jun 21, 2021. doi: 10.3748/wjg.v27.i23.3396
Figure 2 Proportion (%) of Crohn’s disease and ulcerative colitis patients who maintained or initiated new inflammatory bowel disease drugs at the index date.
UC: Ulcerative colitis; CD: Crohn’s disease.
- Citation: Sassaki LY, Miszputen SJ, Kaiser Junior RL, Catapani WR, Bafutto M, Scotton AS, Zaltman C, Baima JP, Ramos HS, Faria MAG, Gonçalves CD, Guimaraes IM, Flores C, Amarante HMBS, Nones RB, Parente JML, Lima MM, Chebli JM, Ferrari MLA, Campos JF, Sanna MGP, Ramos O, Parra RS, da Rocha JJR, Feres O, Feitosa MR, Caratin RF, Senra JT, Santana GO. Real-world treatment patterns and disease control over one year in patients with inflammatory bowel disease in Brazil. World J Gastroenterol 2021; 27(23): 3396-3412
- URL: https://www.wjgnet.com/1007-9327/full/v27/i23/3396.htm
- DOI: https://dx.doi.org/10.3748/wjg.v27.i23.3396